Portal de investigación
COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Rosenberg, Aaron
- Baljevic, Muhamed
- Amor, Adrian Alegre
- Barrientos, Jacqueline
- Bashey, Asad
- Baz, Rachid
- Burgues, Juan Bergua
- Delimpasi, Sosana
- Kastritis, Efstathios
- Latif, Tahir
- Lee, Lisa
- Mateos, Maria-Victoria
- Morillo, Daniel
- Parrondo, Ricardo
- Schiller, Gary
- Curran, Emily
- Kishtagari, Ashwin
- Butler, Thomas
- Cacovean, Alex
- Follit, Courtney
- Mandap, Clarissa
- Morris, Steve
- Khouri, Jack
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Rosenberg,A,Baljevic,M,Amor,AA,Barrientos,J,Bashey,A,Baz,R,Burgues,JB et al. COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330). 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931:CIG MEDIA GROUP, LP. 2023 p.p. 152-153.